Research programme: PI3 kinase inhibitors - Kither Biotech
Latest Information Update: 27 Jul 2016
At a glance
- Originator Kither Biotech
- Class Anti-inflammatories
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Inflammation
Most Recent Events
- 27 Jul 2016 Investigation in Inflammation in Italy (Topical)